Insider Transactions Reported by 12 Insiders of SINOVAC BIOTECH LTD

Symbol: SVA on Nasdaq
Location: Beijing

Quick Takeaways

SVA - SINOVAC BIOTECH LTD has 12 insiders with reported activity on this page.
No net insider buy/sell flow is currently reported for the last year.
Recent transaction rows are available for direct filing-level review.

What Changed

No meaningful buy/sell imbalance is currently visible in the one-year window.
Activity will update as new Forms 3/4/5 are filed.

Why This Matters

This page gives a plain-language issuer insider context before you inspect transaction-level evidence.
Use the filing links below to verify timestamps, codes, and ownership impacts directly from SEC forms.

Official SEC Source

Filed on Form 4

Issuer insider activity is sourced from SEC Forms 3, 4, and 5.

See Original Filing

Insider trading overview

Last 12 months

Insider buy and sell flow is broadly balanced over the last 12 months. No Buy or Sell transactions have been reported since 09 Apr 2025.

Buys

Shares: 0

Insiders: 0

Sells

Shares: 0

Insiders: 0

Net

Shares: 0

Insiders: 0

Window (months)	Buy $	Sell $	Net $
0-3	$0	$0	$0
3-6	$0	$0	$0
6-9	$0	$0	$0
9-12	$0	$0	$0

SINOVAC BIOTECH LTD executives and other stock owners filed with the SEC include:

Name	Relationship	Holdings Value	Valuation	Report Date
Andrew Y. Yan	Director	$69,751,905	Median	18 Mar 2026
Yin Weidong	Chief Executive Officer, Director	$41,145,965	Median	18 Mar 2026
Fu Shan	Director	$38,192,410	Median	18 Mar 2026
Nan Wang	Chief Financial Officer	$2,296,850	Median	18 Mar 2026
Qiang (nmn) Gao	Chief Operation Officer	$1,488,100	Median	18 Mar 2026
Jing (nmn) Li	VP, Quality and Production	$1,471,925	Median	18 Mar 2026
Guang (helen) Yang	Chief Business Officer	$1,118,663	Median	18 Mar 2026
Yuk Lam Lo	Director	$582,300	Median	18 Mar 2026
Simon Anderson	Director	$452,900	Median	18 Mar 2026
Yu (nmn) Wang	Director		Mixed	18 Mar 2026
Shuge Jiao	Director		Mixed	18 Mar 2026
Yu Min Qiu	Director		Mixed	18 Mar 2026

Top shareholders of SINOVAC BIOTECH LTD (13F + 13D/G + 3/4/5)

Grouped by holder across the latest SEC ownership disclosures. Ownership % is shown only when it is directly reported or safely comparable across share classes.

Methodology: rows are grouped by holder and ranked by the holder's primary source value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.

Holder	Source	Role / Reporting	Ownership %	Shares	Holdings Value	12M Net Δ	As of	Details
Vivo Capital IX, LLC	13D/G	—	6.3%	4,539,456	$293,522,587	$0	17 Mar 2025	13D/G
ORBIMED ADVISORS LLC	13F	Company	3.8%	2,718,735	$184,466,170	—	31 Dec 2025	13F
Andrew Y. Yan	3/4/5	Director	15%	10,780,820	$69,751,905	—	18 Mar 2026	3/4/5
Yin Weidong	3/4/5 13D/G	Chief Executive Officer, Director · Weidong Yin	8.8% from 13D/G	6,359,500	$41,145,965	—	18 Mar 2026	3/4/5 13D/G
Fu Shan	3/4/5	Director	8.2%	5,903,000	$38,192,410	—	18 Mar 2026	3/4/5
Vivo Capital, LLC	13F	Company	8.2%	5,903,000	$38,192,410	—	31 Dec 2025	13F
Nan Wang	3/4/5	Chief Financial Officer	0.49%	355,000	$2,296,850	—	18 Mar 2026	3/4/5
Neumann Advisory Hong Kong Ltd	13F	Company	0.44%	315,586	$2,042,000	—	31 Dec 2025	13F
Qiang (nmn) Gao	3/4/5	Chief Operation Officer	0.32%	230,000	$1,488,100	—	18 Mar 2026	3/4/5
Jing (nmn) Li	3/4/5	VP, Quality and Production	0.32%	227,500	$1,471,925	—	18 Mar 2026	3/4/5
Guang (helen) Yang	3/4/5	Chief Business Officer	0.24%	172,900	$1,118,663	—	18 Mar 2026	3/4/5
Yuk Lam Lo	3/4/5	Director	0.13%	90,000	$582,300	—	18 Mar 2026	3/4/5
Simon Anderson	3/4/5	Director	0.1%	70,000	$452,900	—	18 Mar 2026	3/4/5
Aprio Wealth Management, LLC	13F	Company	0%	439	$284,033	—	31 Dec 2025	13F
WELLS FARGO & COMPANY/MN	13F	Company	0.02%	16,876	$109,188	—	31 Dec 2025	13F
SUSQUEHANNA INTERNATIONAL GROUP, LLP	13F	Company	0.02%	16,430	$106,302	—	31 Dec 2025	13F
UBS Group AG	13F	Company	0.01%	9,222	$59,666	—	31 Dec 2025	13F
MORGAN STANLEY	13F	Company	0.01%	9,144	$59,161	—	31 Dec 2025	13F
Horizon Investments, LLC	13F	Company	0%	52	$336	—	31 Dec 2025	13F
1Globe Capital LLC	13D/G	—	32%	18,515,315	—	$0	07 Jul 2025	13D/G
SAIF Partners IV L.P.	13D/G	—	15%	10,780,820	—	$0	15 Dec 2025	13D/G
Advantech Capital L.P.	13D/G	—	8.1%	5,851,423	—	$0	08 Jul 2025	13D/G
Vivo Capital VIII, LLC	13D/G	Vivo Capital IX, LLC	6.3%	4,541,764	—	$0	11 Jul 2025	13D/G

Recent Insider Transactions by Companies or Individuals for SINOVAC BIOTECH LTD

Showing up to 300 most recent insider transactions from the last 12 months.

Insider	Symbol	Class	Shares Owned	Date	Ownership
Jing (nmn) Li	SVA	Common shares, par value $0.001 per share	227,500	18 Mar 2026	Direct
Guang (helen) Yang	SVA	Common shares, par value $0.001 per share	172,900	18 Mar 2026	Direct
Fu Shan	SVA	Common shares, par value $0.001 per share	5,903,000	18 Mar 2026	By Vivo Capital Fund VIII, L.P., Vivo Capital Surplus Fund VIII, L.P. and Vivo Capital Fund IX, L.P.
Simon Anderson	SVA	Common shares, par value $0.001 per share	70,000	18 Mar 2026	Direct
Yin Weidong	SVA	Common shares, par value $0.001 per share	6,359,500	18 Mar 2026	Direct
Andrew Y. Yan	SVA	Common shares, par value $0.001 per share	10,780,820	18 Mar 2026	By SAIF Partners IV L.P.
Qiang (nmn) Gao	SVA	Common shares, par value $0.001 per share	230,000	18 Mar 2026	Direct
Nan Wang	SVA	Common shares, par value $0.001 per share	355,000	18 Mar 2026	Direct
Yuk Lam Lo	SVA	Common shares, par value $0.001 per share	90,000	18 Mar 2026	Direct

* An asterisk sign (*) next to the price indicates that the price is likely invalid.